Twenty-five years of glutamate in schizophrenia: are we there yet?
about
Eyeblink Conditioning in Schizophrenia: A Critical ReviewInhibition of parvalbumin-expressing interneurons results in complex behavioral changes.Social Stress and Psychosis Risk: Common Neurochemical Substrates?Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis.Mismatch negativity (MMN) as an index of cognitive dysfunctionThe role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue.Deletion of striatal adenosine A(2A) receptor spares latent inhibition and prepulse inhibition but impairs active avoidance learningThe longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial.Clinical and biochemical study of d-serine metabolism among schizophrenia patients.Free D-aspartate regulates neuronal dendritic morphology, synaptic plasticity, gray matter volume and brain activity in mammalsAlterations of mGluR5 and its endogenous regulators Norbin, Tamalin and Preso1 in schizophrenia: towards a model of mGluR5 dysregulation.Ketamine and phencyclidine: the good, the bad and the unexpected.Neurodevelopment, GABA system dysfunction, and schizophreniaGenome-wide gene pathway analysis of psychotic illness symptom dimensions based on a new schizophrenia-specific model of the OPCRITAnti-N-methyl-d-aspartate receptor encephalitis in a patient with a 7-year history of being diagnosed as schizophrenia: complexities in diagnosis and treatmentSex differences in GABAergic gene expression occur in the anterior cingulate cortex in schizophrenia.Postnatal neurodevelopmental expression and glutamate-dependent regulation of the ZNF804A rodent homologue.Modulating NMDA Receptor Function with D-Amino Acid Oxidase Inhibitors: Understanding Functional Activity in PCP-Treated Mouse Model.Neurological dysfunctions associated with altered BACE1-dependent Neuregulin-1 signaling.Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes.Cycloid psychoses in the psychosis spectrum: evidence for biochemical differences with schizophreniaCortical synaptic NMDA receptor deficits in α7 nicotinic acetylcholine receptor gene deletion models: implications for neuropsychiatric diseases.Leading compounds for the validation of animal models of psychopathology.Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach.Current and future treatment modalities in schizophrenia: novel antipsychotic drugs and cognitive therapy.The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatmentAntipsychotic treatment modulates glutamate transport and NMDA receptor expression.Anti-NMDA receptor encephalitis, autoimmunity, and psychosis.Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia.A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia.Does Vitamin C Influence Neurodegenerative Diseases and Psychiatric Disorders?Ketamine modulates hippocampal neurochemistry and functional connectivity: a combined magnetic resonance spectroscopy and resting-state fMRI study in healthy volunteersSupplementation with D-serine prevents the onset of cognitive deficits in adult offspring after maternal immune activation.Effects of Ketamine on Resting-State EEG Activity and Their Relationship to Perceptual/Dissociative Symptoms in Healthy Humans.Kynurenine and Tryptophan Levels in Patients With Schizophrenia and Elevated Antigliadin Immunoglobulin G Antibodies.Cough syrup psychosis: Is it under-recognised?Oral acetate supplementation attenuates N-methyl D-aspartate receptor hypofunction-induced behavioral phenotypes accompanied by restoration of acetyl-histone homeostasis.Muscarinic receptor signaling contributes to atypical antipsychotic drug reversal of the phencyclidine-induced deficit in novel object recognition in rats.Ketamine Self-Administration Reduces the Homeostasis of the Glutamate Synapse in the Rat Brain.Serotonin (5-HT)1A receptor agonism and 5-HT7 receptor antagonism ameliorate the subchronic phencyclidine-induced deficit in executive functioning in mice.
P2860
Q26770718-BA003E91-71D9-437B-A936-77CD704CE99DQ27319891-9D468E3A-34B4-496D-9F00-3D09723913BBQ30364687-29E5F4B4-5B9A-4619-8D01-7A121FA97498Q30366961-B789A8DE-8DB1-4370-8AF1-3D90048A353BQ30407708-B970DB56-C0CE-4D80-B8C5-D5F2B5E7535AQ30437188-26F00DA3-F7CD-4AA1-830E-B47AE8B7D8A5Q30440698-D3447548-FE32-4E38-A4BB-3330633F7137Q30702895-6F6E82CC-902F-46BD-A054-3BCDB18E43B9Q33565101-5CBCBF19-59E7-43CA-A2E9-2AFE55EF1A3AQ33990671-041AD672-F57F-4E8D-962D-E95ED8FFC6E7Q34467470-C605CF2B-BCD3-46C2-BA50-A9C2E883E75AQ34480719-2DD100E2-0290-45BC-ABF4-0B3EF650C005Q34675943-A1981166-E895-4534-ABBB-12DADC5A881AQ35537274-FA198938-474A-4309-8B6E-70D546EE6BEBQ35746924-315F9E1C-F962-4D4E-A894-98EC6B6034FEQ35915861-D5E90A5E-C6D6-4209-BED1-2F8B13F4C75FQ36113439-745B5DCB-E3F0-40A4-BD1B-D301A538ADB4Q36642660-4CAD95EF-F6BE-4362-9E71-5CEC9E45FE2FQ36804007-97D21A66-FE96-4908-AFA4-84E2DAB0848DQ36915452-2648EEB0-54A3-41B0-9B2E-08D6934608ACQ37158915-A5AB3B44-B8EA-4123-9D5C-B54F82DED258Q37561567-0F6E3452-FE9A-4E36-BF8F-843BF3F1DE1DQ38128733-35A095E1-EDFE-499B-A9C4-C4366445CE21Q38154625-05F8B3D0-1001-4146-931D-46E0413472B7Q38168861-DBB648C7-20A3-4076-A4D0-543E8B764852Q38213709-6084666C-20DF-437B-A841-5A53E839D485Q38248566-0C62A4D2-678B-4EAF-B46F-17C1B829AE41Q38280193-46FE1154-D6B4-4311-B298-35331976AF28Q38829187-759A2302-356E-45D0-AC52-9637228F25E6Q39220948-79F749B9-F35B-45AE-BACE-3D88A45BF4FDQ39400501-EEBAF587-1434-4BA5-8997-907BEB78B9F9Q39536837-6C173816-8206-444E-831C-06FF68436107Q40448883-9A41ED21-4728-4455-B4D5-ACC1015ADE81Q41187872-5B7893E3-27D6-4B6A-A824-2628EEEA1997Q41656861-CC953169-42C3-4A55-9D4E-1EA121B05123Q43410900-78D2EC22-DE50-4B37-8A6D-456E3637353AQ47595866-562DC5DE-6478-4808-8579-9AD485C293C6Q47925112-50E7B8AB-5B4F-42A1-9A18-BD7532FBA078Q48262648-8EA5A92F-1FAC-4979-9782-40013464333AQ50550002-67D60F6D-B03F-49F6-BABD-7B85F4864529
P2860
Twenty-five years of glutamate in schizophrenia: are we there yet?
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Twenty-five years of glutamate in schizophrenia: are we there yet?
@en
Twenty-five years of glutamate in schizophrenia: are we there yet?
@nl
type
label
Twenty-five years of glutamate in schizophrenia: are we there yet?
@en
Twenty-five years of glutamate in schizophrenia: are we there yet?
@nl
prefLabel
Twenty-five years of glutamate in schizophrenia: are we there yet?
@en
Twenty-five years of glutamate in schizophrenia: are we there yet?
@nl
P2860
P356
P1476
Twenty-five years of glutamate in schizophrenia: are we there yet?
@en
P2860
P304
P356
10.1093/SCHBUL/SBS100
P407
P577
2012-09-01T00:00:00Z